EyePoint, Inc. (NASDAQ: EYPT) Securities Fraud Investigation

EyePoint Reports Disappointing Phase 3 Clinical Trials  
On August 17, 2026, EyePoint issued a press release “announc[ing] topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU™ (vorolanib intravitreal insert) for the treatment of wet age-related macular degeneration (wet AMD).”  Specifically, EyePoint disclosed that DURAVYU did not meet the prespecified primary endpoint — change in best-corrected visual acuity versus on-label aflibercept — in the full dataset of the company’s Phase 3 LUGANO trial in wet age-related macular degeneration.

EyePoint’s Stock Drops Over 66%
Following the news of EyePoint, Inc.’s poor clinical trial results, the company’s stock price fell over 66%.

If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP:  Jonathan Naji, Esq. (484) 270-1453 or via e-mail at [email protected].  

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: 
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs’ Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.